

Solicited Program Adverse Event/Special Situation Report Form

GF-21045H.03

Please complete as many details as possible and forward within one business day to:

Program Details						
Name of Program: HCV Elimination Project				Form Completed By		
Name of Organisation: Mrcheveli				Print Name: Jaba Zarkua		
Date aware of Safety Information: 31.10,15				Signature: This Telephone Number: 597 39 01 00		
Country of Occurrence of Safety Information Georgia				Fax No/Email: Jabazarqua Ogmail. com		
Patient Details	HALL					
Age: 52 1	nitials: G. k.	Sex:	Male 🗹 Fer	male DOB: 15/0	7/1963 (or year of b	pirth):
Drug Details (Provide	additional drugs on a	separate pag	je)			
Drug Name	Dose	Route	Start Date (DD/MON/YYYY)	Stop Date (or On-going) (DD/MON/YYYY)	Reason For Taking	Lot/Batch No
Sovaldi	400mg	PO	27/10/2015	On-going	HCV	SFMTD+
Peg. Interferon a 28	150 mkg	SC	27/10/2015	31/10/2015	HCV	5RCJA 871
Ribaririn	1200mg	PO	27/10/2015	On-going	HCV	410 1407
week of treatment on his back,	treatment (under ar	nt w 30/10/1 m am	os inici 5) patient d abdome	ated on 23 has reporte in. Interfere	tholls. Duci ed urticaria n was stop	ng tirst l rush ped promptly.
Does the Reporter conside drug? Yes ☑	r that the event(s)	were possibl		as this safety information pruthority? Yes	eviously been reported to	a Regulatory
Reporter Details (i.e	. who notified you	of the above	safety information?)			
*If the Reporter is a Non-	ncare Professiona	al (HCP) and sional, plea	d they are willing to asse confirm if they ar	on-healthcare professional provide us with their contact willing to provide contact.	act information, please re	ecord below
HCP Name:	details belov	(V)	No 🗌	CP Address		
				First Line:		
HCP Telephone No/FAX No:				Town/City:		
HCP Email:				County/State: Postcode/Zip code:		

Please be aware that information provided to Gilead relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by Gilead in accordance with applicable data protection laws and the Gilead privacy policy, available to you either on www.gilead.com/privacy or upon request.